Closely-held Zucara Therapeutics expects to release results in the second quarter of its Phase 1b proof-of-concept study with its once-daily drug candidate, ZT-01, to prevent insulin-induced hypoglycemia, or low blood...

Closely-held Illuminate Health is leveraging a technology-enabled continuous medication management platform to help patients optimize medications at home to improve treatment adherence and reduce hospitalizations. 

As a co-founder and CEO of closely-held Cellares, which is pioneering an automated approach to cell therapy manufacturing, Fabian Gerlinghaus, an aerospace engineer by training, made the switch to biotech eight years...

Recently launched Lanier Biotherapeutics is developing specialty biologic treatments for indications in multifunctional retina, dermatology and Type 2 inflammation diseases.

In a bid to counter the next great health crisis, ContraFect (NASDAQ:CFRX) is in late-stage development of a new modality to treat life-threatening and antibiotic-resistant infections, using direct lytic agents (DLAs).

Aptevo Therapeutics (NASDAQ:APVO) has developed a broad portfolio of potential immuno-oncology therapies with multiple mechanisms of action from two differentiated bispecific and multi-specific antibody platform...

With an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease, ReShape Lifesciences (NASDAQ:RSLS) is reshaping patients minds, bodies and lives.

Closely-held Bombi Biomics of the Netherlands has developed a technology known as Bombilysin with the potential to kill bacteria from the outside shell in contrast to conventional antibiotics that typically are intended...